title: Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease.
abstract: BACKGROUND
  The treatment of Kawasaki disease patients who fail to respond to initial i.v. immunoglobulin (IVIG) therapy is controversial. The aim of the present study was to investigate the long-term efficacy of plasma exchange (PE) treatment for refractory Kawasaki disease.
  
  
  METHODS
  A total of 125 Kawasaki disease patients refractory to IVIG were treated with PE. Coronary artery lesions (CAL) before PE, in the acute period, and during the late period were examined retrospectively.
  
  
  RESULTS
  Residual sequelae requiring medical treatment occurred in six cases in the late period. The outcomes of treatment tended to be better when PE was begun in the early stage. Sequelae remained in 2.8% of patients in whom PE was initiated prior to day 9 after onset, and were present in 15% of patients in whom PE was started on or after day 10. The 105 patients whose coronary arteries were normal before PE had no sequelae (residual sequelae: 0%). Dilatation was present before PE in 14 patients, but remained in only two patients in the late period (residual sequelae, 14.3%). In four of the six patients in whom aneurysms had already formed before PE, the lesions had advanced into giant aneurysms, but in the other two patients they returned to the normal range (residual sequelae, 66.6%).
  
  
  CONCLUSIONS
  The outcomes of PE for Kawasaki disease refractory to IVIG are favorable, and the effectiveness of this treatment is excellent, particularly if it is initiated before CAL arise.
authors: Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan. thokosaki@hotmail.co.jp
authors: Tatsunori
authors: T
authors: Hokosaki
authors: Masaaki
authors: M
authors: Mori
authors: Takashi
authors: T
authors: Nishizawa
authors: Tomoko
authors: T
authors: Nakamura
authors: Tomoyuki
authors: T
authors: Imagawa
authors: Mari
authors: M
authors: Iwamoto
authors: Shumpei
authors: S
authors: Yokota
mesh_terms: D002648:Child; D002675:Child, Preschool; D003331:Coronary Vessels / Q000473:pathology*; D004108:Dilatation, Pathologic / Q000628:therapy; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000628:therapy*; D010951:Plasma Exchange / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous